<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098704</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2017/45</org_study_id>
    <nct_id>NCT05098704</nct_id>
  </id_info>
  <brief_title>Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk</brief_title>
  <acronym>PSSIT</acronym>
  <official_title>Phase II/III Double-blind Randomized Placebo-controlled Trial Assessing the Preventive Effect of Clopidogrel on the Systemic Sclerosis Development Risk in Subjects With Specific Dysimmunity and Raynaud Phenomenon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry for Health and Solidarity, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic sclerosis (SSc) is a severe autoimmune disease associating dysimmunity, vasculopathy&#xD;
      and fibrosis. No curative treatment is available. Pre-clinical abnormalities can be found&#xD;
      such as specific autoantibodies. The association of Raynaud phenomenon and SSc-specific&#xD;
      anti-nuclear antibodies is the hallmark of pre-scleroderma subjects, among who around 47%&#xD;
      declare a complete disease after five years. The aim of this study is to assess in this&#xD;
      particular population the preventive effect of an anti-platelet treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, platelet activation is targeted as it could play a key role in the&#xD;
      pathogenesis of SSc. It has been shown in several publications that platelets are activated&#xD;
      in SSc with a correlation between the level of activation and disease activity. Secondary to&#xD;
      this activation, soluble and membrane effectors were increased, and induced vascular damages&#xD;
      and fibrosis. The results obtained in the laboratory (CNRS UMR-5164) directly involved&#xD;
      platelets in this mechanism by inducing the thymic stromal lymphopoietin (TSLP) production by&#xD;
      endothelial cells and by showing the pro-fibrotic effect of TSLP. In vivo data in SSc murine&#xD;
      model recently obtained, confirmed the preventive role on fibrosis of clopidogrel. The early&#xD;
      control of this platelet activation could prevent the course of events leading to SSc.&#xD;
&#xD;
      The therapeutic strategy assessed in this study will be the oral administration of&#xD;
      clopidogrel (75 mg per day) during two years to subjects presenting an association of&#xD;
      specific dysimmunity and Raynaud phenomenon (RP). The administration of clopidogrel will be&#xD;
      double-blinded versus placebo.&#xD;
&#xD;
      Subjects will be included and treated during a 2-year period and will be followed for a&#xD;
      period of 36 months after treatment, i.e. a total of 60 months. The follow-up will be every&#xD;
      six months mainly comprising clinical examination, patient reported outcomes and blood&#xD;
      sampling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">January 2029</completion_date>
  <primary_completion_date type="Anticipated">January 2029</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of occurrence of SSc at 5 years according to American College of Rheumatology (ACR) / European League Against Rhumatism (EULAR) 2013 criteria in the two randomization groups</measure>
    <time_frame>60 months after baseline (Day 0)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of occurrence of cutaneous fibrosis (sclerodactyly or other affected area) clinically assessed by at least 2 independent investigators in the two randomization groups</measure>
    <time_frame>60 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of modified Rodnan skin score (which varies between 0 and 51, with higher values mean higher disease severity) in the two randomization groups.</measure>
    <time_frame>60 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean of Cochin hand function scale (which varies between 0 and 90, with higher values mean higher disease severity) in the two randomization groups.</measure>
    <time_frame>60 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of sex ratio at inclusion in the two randomization groups.</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean age at inclusion in the two randomization groups.</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients exposed to toxic products at inclusion in the two randomization groups.</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients exposed to toxic products at 5 years in the two randomization groups.</measure>
    <time_frame>60 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients affected by a limited form of SSc at 5 years in the two randomization groups.</measure>
    <time_frame>60 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients affected by a diffuse form of SSc at 5 years in the two randomization groups.</measure>
    <time_frame>60 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients presenting a specific antibody positivity (anti-scl70, anti-centromere) in the two randomization groups at inclusion.</measure>
    <time_frame>At baseline (Day 0)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients presenting megacapillaries by capillaroscopy at 5 years in the two randomization groups.</measure>
    <time_frame>60 months after baseline (Day 0)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Scleroderma</condition>
  <condition>Systemic Sclerosis</condition>
  <arm_group>
    <arm_group_label>clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clopidogrel treatment</intervention_name>
    <description>75 mg daily during 24 months</description>
    <arm_group_label>clopidogrel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>75 mg daily during 24 months</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old, and less than 85 years old.&#xD;
&#xD;
          -  Patient with positive AAN (AAN â‰¥ 1/160) with the following specificity: anti-Scl70 or&#xD;
             anti-centromere or anti-RNApolIII.&#xD;
&#xD;
          -  Patient with RP reported by the subject and confirmed by the physician.&#xD;
&#xD;
          -  Patient affiliated to a health insurance system.&#xD;
&#xD;
          -  Patient who accepts to participate to the study and signs an inform consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with an SSc diagnosis according to ACR/EULAR 2013 criteria.&#xD;
&#xD;
          -  Patient with skin fibrosis at screening.&#xD;
&#xD;
          -  Patient with antiplatelet treatment at screening.&#xD;
&#xD;
          -  Patient with contraindications to clopidogrel.&#xD;
&#xD;
          -  Patient treated by immunosuppressive agent at screening.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Women of childbearing age refusing effective contraception method during the study.&#xD;
&#xD;
          -  Incompetent adults (i.e. Individuals under the protection of a conservator)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie-Elise TRUCHETET, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Linda WITTKOP, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie-Elise TRUCHETET, Prof</last_name>
    <phone>05.56.79.55.56</phone>
    <phone_ext>+33</phone_ext>
    <email>marie-elise.truchetet@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas BARNETCHE, PhD</last_name>
    <email>thomas.barnetche@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de rhumatologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marie-Elise TRUCHETET, Prof</last_name>
      <email>marie-elise.truchetet@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Thomas BARNETCHE, PhD</last_name>
      <email>thomas.barnetche@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Marie-Elise TRUCHETET, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joel CONSTANS, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre DUFFAU, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien SENESCHAL, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Estibaliz LAZARO, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Brest - service de rhumatologie</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain SARAUX, Prof</last_name>
      <email>alain.saraux@chu-brest.fr</email>
    </contact>
    <investigator>
      <last_name>Alain SARAUX, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges - Service de mÃ©decine interne</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anne-Laure FAUCHAIS, Prof</last_name>
      <email>anne-laure.fauchais@unilim.fr</email>
    </contact>
    <investigator>
      <last_name>Anne-Laure FAUCHAIS, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Mont-de-Marsan - service de rhumatologie</name>
      <address>
        <city>Mont-de-Marsan</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Marion MIRABEL, MD</last_name>
      <email>marion.mirabel@ch-mdm.fr</email>
    </contact>
    <investigator>
      <last_name>Marion MIRABEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier - service de rhumatologie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Jacques MOREL, Prof</last_name>
      <email>j-morel@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques MOREL, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Pau - service de mÃ©decine interne</name>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier DELBREL, MD</last_name>
      <email>xavier.delbrel@ch-pau.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier DELBREL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse - service de mÃ©decine interne</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>GrÃ©gory PUGNET, MD</last_name>
      <email>pugnet.g@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>GrÃ©gory PUGNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 4, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>systemic sclerosis</keyword>
  <keyword>clopidogrel</keyword>
  <keyword>platelet</keyword>
  <keyword>prevention</keyword>
  <keyword>primary care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

